1. Acton, E. M. and Tong, G. L. (1981). Synthesis and preliminary antitumour evaluation of 5-iminodoxorubicin. J. Med. Chem., 24, 669–673
2. Allan, S. G., Cummings, J., Evans, S., Nicolson, M., Stewart, M. E., Cassidy, J., Soukop, M., Kaye, S. B. and Smyth, J. F. (1991). Phase I study of the anthra-pyrazole biantrazole: clinical results and pharmacology. Cancer Chemother. Pharmacol., 28, 55–58
3. Ames, M. M., Loprinzi, C. L., Collins, J. M., van Haelst-Pisani, C, Richardson, R. L., Rubin, J. and Moertel, C. G. (1990). Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole). Cancer Res., 50, 3905–3909
4. Basra, J., Wolf, C. R., Brown, J. R. and Patterson, L. H. (1985). Evidence for human liver mediated free-radical formation by doxorubicin and mitozantrone. Anti-cancer Drug Des., 1, 45–52
5. Burchenal, J. H., Pancost, T. and Elslager, E. (1985). Anthrapyrazole and amsa-crine analogs in mouse and human leukaemia in vitro andin vivo. Proc. Am. Assoc. Cancer Res., 26, 224